Amgen sales and marketing update

AMGN announced that it expects a modest reduction in the growth rate of sales of Epogen erythropoietin for 1997 based on new Medicare reimbursement guidelines

Read the full 253 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE